BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Buyback Yield

Buyback Yield of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026.

Buyback Yield

0.00

Last updated:

Buyback Yield of BrightGene Bio-Medical Technology Co is 2025 0.00 . Buyback Yield of BrightGene Bio-Medical Technology Co was 2024 0.00 . It decreases by % lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Buyback Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Buyback Yield
Date
Buyback Yield
Jan 1, 2018
0.00 CNY
Jan 1, 2019
0.00 CNY
Jan 1, 2020
0.00 CNY
Jan 1, 2021
0.00 CNY
Jan 1, 2022
0.00 CNY
Jan 1, 2023
0.00 CNY
Jan 1, 2024
0.00 CNY
Jan 1, 2025
0.00 CNY
The BrightGene Bio-Medical Technology Co Buyback Yield history
YEARBuyback YieldYoY
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

On Eulerpool you can find the complete historical development of Buyback Yield BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Buyback yield measures the percentage of market cap returned to shareholders through share repurchases. It complements dividend yield in assessing total shareholder returns.

To evaluate Buyback Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Buyback Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Buyback Yield's BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co